DrugAdopt
Weeks of bioinformatics, delivered in days.
An analytics team that works with you directly, with nothing to install.
Days, not weeks
We compress weeks of bioinformatics work into a few days.
Hands-on support
We iterate with you until the analysis answers the question you actually have.
No installs, no IT
Nothing to set up or approve. You keep control of your data.
Biomarkers built in
Biomarker identification is part of every analysis, so findings hold up better.
What’s in a case
Every angle of your drug, in one evidence package.
DrugAdopt takes one drug in one indication through eleven evidence modules, from disease biology to the patent record. A separate reviewer checks each module, and every finding links back to its source.
Scoping and orientation
We confirm what the drug is, define the question, and map what is publicly known about the drug, disease, trials and datasets before the deeper work begins.
-
Disease and target biology
- Disease frame
- How the disease progresses, and how it is staged and measured.
- Target validation
- Whether the target rationale holds up, and where it stops.
- Dependency
- Whether perturbing the mechanism changes a disease-relevant phenotype in models.
-
Safety and exposure
- Safety
- How mechanistic, nonclinical and human safety evidence compare.
- ADMET and PK/PD
- Whether exposure is plausibly compatible with both activity and safety.
-
Clinic, competition and IP
- Clinical
- Which endpoints have precedent, what they can detect, and whether a trial can enroll.
- Competition
- Who else is developing in the field, and the dated public evidence for each program.
- IP landscape
- Who holds the public patent record, with key term dates. A landscape, not a legal opinion.
One synthesized report
Findings are joined across modules to answer your question, with the contradictions, open gaps and the data that would close them. You get the evidence; the decisions stay yours.